End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
54.78 CNY | +0.61% | -2.89% | +3.48% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.48% | 1.99B | - | ||
+38.59% | 727B | C+ | ||
-7.89% | 354B | C+ | ||
+15.66% | 328B | B- | ||
+0.24% | 277B | C+ | ||
+13.47% | 243B | B+ | ||
+7.35% | 205B | B- | ||
-6.42% | 203B | A+ | ||
+4.23% | 164B | C+ | ||
-1.70% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 688266 Stock
- Ratings Suzhou Zelgen Biopharmaceuticals Co.,Ltd.